Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrons01:10

Nephrons

3.6K
The kidneys are intricate organs with millions of working units known as nephrons. Each nephron features two major structures: the renal corpuscle, which facilitates blood plasma filtration, and the renal tubule, which handles the glomerular filtrate. Blood supply is directly linked to the nephrons. The renal corpuscle consists of the glomerulus, a capillary network, and the Bowman's capsule, a double-walled epithelial structure that encases the glomerulus. The filtering of blood plasma...
3.6K
Renal Corpuscle01:20

Renal Corpuscle

3.6K
The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
3.6K
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

94
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
94
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

132
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
132
External Anatomy of the Kidney01:21

External Anatomy of the Kidney

1.8K
The kidneys are a pair of bean-shaped organs in the human body that play a critical role in maintaining overall health. They filter out waste products from the blood, regulate blood pressure, maintain electrolyte balance, and stimulate the production of red blood cells.
The kidneys are located in the retroperitoneal space on either side of the vertebral column, protected posteriorly by the 11th and 12th ribs. The right kidney sits slightly lower than the left owing to the presence of the liver...
1.8K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

95
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
95

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-Polyamine Therapy Restrains Kidney Cyst Growth in an Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease.

bioRxiv : the preprint server for biology·2026
Same author

Metabolite patterns in human urine after oral administration of highly purified Δ8-THCV.

Forensic toxicology·2026
Same author

The authors reply.

Kidney international·2026
Same author

Endocannabinoids, perioperative pain, and acetaminophen in patients undergoing total knee arthroplasty: a prospective cohort study.

Pain reports·2026
Same author

Age differences in endocannabinoid tone are ameliorated after recent cannabis use.

Scientific reports·2026
Same author

High doses of orally administered cannabigerol produce deficits in sustained attention in female rats.

Pharmacology, biochemistry, and behavior·2026

Related Experiment Video

Updated: Oct 1, 2025

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

9.9K

Endocannabinoid System in Polycystic Kidney Disease.

Jost Klawitter1, Cristina Sempio1, Matthew J Jackson1

  • 1Deparment of Anesthesiology, University of Colorado Denver, Denver, Colorado, USA.

American Journal of Nephrology
|March 9, 2022
PubMed
Summary

Autosomal dominant polycystic kidney disease (ADPKD) patients have lower endocannabinoid (EC) levels. Restoring EC balance, particularly anandamide (AEA) and palmitoylethanolamide (PEA), may offer a promising therapeutic strategy for ADPKD.

Keywords:
2-ArachidonoylglycerolAnandamideAutosomal dominant polycystic kidney diseaseEndocannabinoids

More Related Videos

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.6K
Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease
12:47

Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease

Published on: February 3, 2012

38.7K

Related Experiment Videos

Last Updated: Oct 1, 2025

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

9.9K
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.6K
Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease
12:47

Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease

Published on: February 3, 2012

38.7K

Area of Science:

  • Nephrology
  • Endocrinology
  • Immunology

Background:

  • Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder causing renal cysts and interstitial inflammation.
  • The kidney expresses the endocannabinoid (EC) system, which plays a role in inflammation and kidney disease progression.

Purpose of the Study:

  • To investigate endocannabinoid (EC) levels in patients with ADPKD.
  • To explore the association between EC levels and disease progression in ADPKD.

Main Methods:

  • A validated mass spectrometry assay was used to measure EC levels in 102 ADPKD patients and 100 healthy controls.
  • Blood samples were collected at baseline and after 2 and 4 years, with patients on standard or rigorous blood pressure control.

Main Results:

  • ADPKD patients exhibited higher interleukins-6 and -1b, and lower plasma levels of anandamide (AEA), 2-arachidonoyl-glycerol (2-AG), and related compounds compared to controls.
  • Lower baseline AEA levels correlated with greater ADPKD progression (increased kidney volume) and poorer renal function (decreased eGFR).
  • Palmitoylethanolamide (PEA) levels positively correlated with renal function improvement (eGFR change).

Conclusions:

  • ADPKD is associated with reduced levels of key endocannabinoids (ECs).
  • Augmenting AEA, PEA, and 2-AG levels, by enhancing synthesis or reducing degradation, could be a potential therapeutic approach for ADPKD.
  • Targeting the renal EC system presents a promising avenue for ADPKD treatment.